Trial Profile
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Folinic acid; Folinic acid; Mercaptopurine; Methotrexate; Pegaspargase; Pegaspargase; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Biomarker; Therapeutic Use
- 04 Apr 2024 Status changed from active, no longer recruiting to recruiting.
- 16 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2022 Planned number of patients changed from 87 to 80.